TRAVERE THERAPEUTICS INC's ticker is TVTX and the CUSIP is 89422G107. A total of 176 filers reported holding TRAVERE THERAPEUTICS INC in Q1 2023. The put-call ratio across all filers is 1.28 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $16,161,213 | -31.1% | 1,807,742 | +18.3% | 0.43% | -22.4% |
| Q2 2023 | $23,465,779 | -18.3% | 1,527,720 | +19.7% | 0.56% | -18.5% |
| Q1 2023 | $28,711,859 | +43.5% | 1,276,650 | +34.2% | 0.68% | +42.1% |
| Q4 2022 | $20,013,200 | -14.7% | 951,650 | 0.0% | 0.48% | -20.5% |
| Q3 2022 | $23,449,000 | +1.7% | 951,650 | 0.0% | 0.61% | -9.7% |
| Q2 2022 | $23,058,000 | -6.0% | 951,650 | 0.0% | 0.67% | +8.8% |
| Q1 2022 | $24,524,000 | -17.0% | 951,650 | 0.0% | 0.62% | -9.5% |
| Q4 2021 | $29,539,000 | -18.6% | 951,650 | -36.4% | 0.68% | -10.6% |
| Q3 2021 | $36,298,000 | +66.5% | 1,496,817 | +0.2% | 0.76% | +77.0% |
| Q2 2021 | $21,800,000 | -40.8% | 1,494,164 | +1.3% | 0.43% | -46.4% |
| Q1 2021 | $36,845,000 | +32.4% | 1,475,564 | +44.5% | 0.80% | +36.3% |
| Q4 2020 | $27,827,000 | – | 1,021,000 | – | 0.59% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Lynx1 Capital Management LP | 411,680 | $10,609,000 | 9.85% |
| VR Adviser, LLC | 1,994,997 | $51,411,000 | 8.33% |
| Kynam Capital Management, LP | 870,918 | $22,444,000 | 7.28% |
| GREAT POINT PARTNERS LLC | 1,010,000 | $26,028,000 | 6.29% |
| Deep Track Capital, LP | 3,134,503 | $80,776,000 | 5.18% |
| RA Capital Management | 4,922,941 | $126,864,000 | 2.77% |
| ARMISTICE CAPITAL, LLC | 4,958,000 | $127,768,000 | 2.47% |
| MPM BioImpact LLC | 277,950 | $7,163,000 | 1.92% |
| Sofinnova Investments, Inc. | 658,249 | $16,963,000 | 1.29% |
| Perceptive Advisors | 1,845,555 | $47,560,000 | 0.95% |